COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

After completing the transformation of big data, the pharmaceutical industry will enter the era of "expressway"

Page view
After completing the transformation of big data, the pharmaceutical industry will enter the era of "expressway"
 
 
 
 
Nowadays, "big data" has improved people's lives in various aspects. Similarly, in the pharmaceutical industry, big data has become the core basic ability. It is predicted in the industry that in the next 5-10 years, digitization will increase the efficiency of Chinese pharmaceutical enterprises by 3-5 times, and the development of pharmaceutical enterprises that have completed digitization transformation will enter the era of "expressway".
 
 
 
 
According to the outline of the "healthy China 2030" plan, the total size of the health service industry will reach 16 trillion yuan by 2030, bringing unprecedented development opportunities to China's life and health industry. In the face of such a huge market size and innovation opportunities, pharmaceutical enterprises should seize the opportunity of big data and promote enterprise upgrading.
 
 
 
 
Digital technologies, such as artificial intelligence, machine learning, big data and mobile healthcare, are reshaping the pharmaceutical industry and giving it a new look, analysts said. At present, the domestic pharmaceutical industry is also undergoing digital transformation under the influence of policies, markets and enterprises' own wishes. It is reported that in recent years, the changes in domestic medical policies are larger than ever before, and throughout the medical, medical, medical insurance and other aspects, is a systematic and comprehensive impact.
 
 
 
 
At present, the wave of digital transformation is taking place in the domestic pharmaceutical industry. One of the core competitiveness of pharmaceutical companies in the future should be digitalization. The application of big data will also bring new changes to the pharmaceutical industry. For example, in the research and development of prescription drugs, it is self-evident that big data analysis can reduce the cost of data management and achieve rapid innovation. In terms of drug quality supervision, big data is also of great significance.
 
 
 
 
An industry insider said: "the establishment of digital drugs, the establishment of a nationwide regulatory mechanism, 1.4 billion people regulatory power than the food and drug administration. It used to be all you had to do was cheat the food and drug administration, and with digital drugs you have to cheat 1.4 billion people, including your raw material suppliers, inspectors, packaging materials, all the people involved in the drug manufacturing process. The establishment of digital medicine makes it very expensive for enterprises to cheat.
 
 
 
 
"We integrate data across all areas, whether it's enterprise data, regulatory innovation data, healthcare and market data. Based on this data, we built a database in this field. In addition, industry insiders say that when an industry is structured with data, it will accelerate the coordination and development of the industry to a faster degree.
 
 
 
 
Big data provides an unprecedented opportunity for the pharmaceutical industry to optimize research and clinical trials, guard against counterfeiting and fraud, improve treatment outcomes, and target physicians with timely and relevant information. Investing in data management will enable the industry to combine real-time and historical information at the speed business requires. Pharmaceutical executives are increasingly aware of the value of data in providing a competitive advantage.
 
 
 
 
The application of big data will bring significant changes to the development of the pharmaceutical industry. Big data is of great significance in the development of new drugs, pharmaceutical production and quality supervision. However, some analysts pointed out that many pharmaceutical companies are actively carrying out big data transformation and upgrading, but there are also some problems in the upgrading process. For example, some people turn pharmaceutical companies into Internet companies, and fight in unfamiliar fields.
 
 
 
 
With the coming of the big health industry in the future, there will be great challenges and development opportunities for the health industry in the future. Big data has a promising future in the pharmaceutical industry, and pharmaceutical companies need to constantly overcome various difficulties to promote the development of big data. It is expected that by 2022, pharmaceutical companies will use streamlined operation mode to obtain research and development funds and achieve more cost-effective medical innovation. Industrial development has enabled pharmaceutical companies to achieve anticipated productivity gains in different sectors and regions. Companies that did well in industrialisation were able to drive consolidation, reducing r&d cycles by 30 per cent and increasing productivity by 40 per cent. By 2022, medical data will become a key infrastructure and key enterprise asset for national development, and will attract a large amount of investment.